Literature DB >> 24775811

Role of testis sparing surgery in the conservative management of small testicular masses: oncological and functional perspectives.

M Borghesi1, E Brunocilla2, R Schiavina2, G Gentile2, H Dababneh2, L Della Mora2, C del Prete2, A Franceschelli3, F Colombo3, G Martorana2.   

Abstract

INTRODUCTION: Radical orchiectomy (RO) is still considered the standard of care for malignant germ cell tumours, which represent the vast majority of the palpable testicular masses. In those patients diagnosed with small testicular masses (STMs), testis-sparing surgery (TSS) could be an alternative treatment to RO. The aim of this updated review is to evaluate the current indications for TSS, and discuss the oncological and functional results of patients who had undergone organ-sparing surgery for STMs. EVIDENCE ACQUISITION: A non-systematic review of the Literature using the Medline database has been performed, including a free-text protocol using the terms "testis-sparing surgery", "testicular sparing surgery", "partial orchiectomy", "testis tumour", "sex cord tumour", and "testis function". Other significant studies cited in the reference lists of the selected papers were also evaluated. EVIDENCE SYNTHESIS: No randomized controlled trials comparing TSS with radical orchiectomy have been reported yet. In those patients with normal contra-lateral testis, the use of TSS is still controversial. In selected cases of gonadal masses < 2 cm, TSS seems to be a safe and feasible treatment option. Frozen section examination allows us to discriminate between benign and malignant neoplasms during TSS. Intermediate and long-term follow-up results showed no significant risk of local and distant recurrences in the main series reported in the literature.
CONCLUSIONS: TSS is an effective treatment for STMs in selected patients, limiting the unnecessary surgical over-treatments, without compromising the oncological and functional outcomes. Further studies are needed in order to confirm the oncological safety.
Copyright © 2013 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cirugía conservadora testicular; Functional outcomes.; Neoplasias testiculares; Oncological outcomes; Orquiectomía radical; Pequeñas masas testiculares; Radical orchiectomy; Resultados funcionales.; Resultados oncológicos; Small testicular masses; Testicular neoplasms; Testis sparing surgery

Mesh:

Year:  2014        PMID: 24775811     DOI: 10.1016/j.acuro.2014.02.020

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  5 in total

1.  Testis-sparing surgery for testicular tumors in children: a 20 year single center experience and systematic review of the literature.

Authors:  Juan I Bois; Roberto L Vagni; Francisco I de Badiola; Juan M Moldes; Paul D Losty; Pablo A Lobos
Journal:  Pediatr Surg Int       Date:  2021-01-17       Impact factor: 1.827

Review 2.  Testis-preserving strategies in testicular germ cell tumors and germ cell neoplasia in situ.

Authors:  Pia Paffenholz; David Pfister; Axel Heidenreich
Journal:  Transl Androl Urol       Date:  2020-01

3.  Testicular yolk sac tumors in children: a review of 61 patients over 19 years.

Authors:  Yi Wei; Shengde Wu; Tao Lin; Dawei He; Xuliang Li; Junhong Liu; Xing Liu; Yi Hua; Peng Lu; Guanghui Wei
Journal:  World J Surg Oncol       Date:  2014-12-29       Impact factor: 2.754

4.  Trends of testis-sparing surgery for pediatric testicular tumors in South China.

Authors:  Yun-Lin Ye; Qiu-Ming He; Fu-Fug Zheng; Sheng-Jie Guo; Fang-Jian Zhou; Zi-Ke Qin
Journal:  BMC Surg       Date:  2017-03-27       Impact factor: 2.102

5.  Clinical presentation, management and follow-up of 83 patients with Leydig cell tumors of the testis: a prospective case-cohort study.

Authors:  Carlotta Pozza; Riccardo Pofi; Marta Tenuta; Maria Grazia Tarsitano; Emilia Sbardella; Giorgio Fattorini; Vito Cantisani; Andrea Lenzi; Andrea M Isidori; Daniele Gianfrilli
Journal:  Hum Reprod       Date:  2019-08-01       Impact factor: 6.918

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.